{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:04:56Z","timestamp":1783713896124,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-023-02109-9","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T05:20:55Z","timestamp":1683782455000},"page":"1099-1108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy"],"prefix":"10.1007","volume":"60","author":[{"given":"Hussein","family":"Zaitoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Lubetzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achiya Z.","family":"Amir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadar","family":"Moran-Lev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liora","family":"Sagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Yacobi-Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ophir","family":"Borger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Chorna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Lebenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-8264","authenticated-orcid":false,"given":"Avivit","family":"Brener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"2109_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S2213-8587(22)00047-X","volume":"10","author":"H Jebeile","year":"2022","unstructured":"Jebeile H, Kelly AS, O\u2019Malley G, Baur LA (2022) Obesity in children and adolescents: epidemiology, causes, assessment, and management. Lancet Diabetes Endocrinol 10:351\u2013365. https:\/\/doi.org\/10.1016\/S2213-8587(22)00047-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2109_CR2","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/S41366-019-0357-5","volume":"44","author":"C Serra-Juh\u00e9","year":"2020","unstructured":"Serra-Juh\u00e9 C, Martos-Moreno G, Bou de Pieri F et al (2020) Heterozygous rare genetic variants in non-syndromic early-onset obesity. Int J Obes (Lond) 44:830\u2013841. https:\/\/doi.org\/10.1038\/S41366-019-0357-5","journal-title":"Int J Obes (Lond)"},{"key":"2109_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/S41576-021-00414-Z","volume":"23","author":"RJF Loos","year":"2022","unstructured":"Loos RJF, Yeo GSH (2022) The genetics of obesity: from discovery to biology. Nat Rev Genet 23:120\u2013133. https:\/\/doi.org\/10.1038\/S41576-021-00414-Z","journal-title":"Nat Rev Genet"},{"key":"2109_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1542\/9781581109405-genetic","volume":"28","author":"VV Thaker","year":"2017","unstructured":"Thaker VV (2017) Genetic and epigenetic causes of obesity. Adolesc Med State Art Rev 28:379\u2013405. https:\/\/doi.org\/10.1542\/9781581109405-genetic","journal-title":"Adolesc Med State Art Rev"},{"key":"2109_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/B978-0-12-820683-6.00022-1","volume":"181","author":"IS Farooqi","year":"2021","unstructured":"Farooqi IS (2021) Monogenic human obesity syndromes. Handb Clin Neurol 181:301\u2013310. https:\/\/doi.org\/10.1016\/B978-0-12-820683-6.00022-1","journal-title":"Handb Clin Neurol"},{"key":"2109_CR6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/J.GENDIS.2021.06.010","volume":"9","author":"F Liu","year":"2022","unstructured":"Liu F, Zhu X, Jiang X et al (2022) Transcriptional control by HNF-1: emerging evidence showing its role in lipid metabolism and lipid metabolism disorders. Genes Dis 9:1248. https:\/\/doi.org\/10.1016\/J.GENDIS.2021.06.010","journal-title":"Genes Dis"},{"key":"2109_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/J.NMD.2020.02.011","volume":"30","author":"A Brener","year":"2020","unstructured":"Brener A, Lebenthal Y, Shtamler A et al (2020) The endocrine manifestations of spinal muscular atrophy, a real-life observational study. Neuromuscul Disord 30:270\u2013276. https:\/\/doi.org\/10.1016\/J.NMD.2020.02.011","journal-title":"Neuromuscul Disord"},{"key":"2109_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/J.NEUINT.2019.04.010","volume":"128","author":"NK Smith","year":"2019","unstructured":"Smith NK, Hackett TA, Galli A, Flynn CR (2019) GLP-1: molecular mechanisms and outcomes of a complex signaling system. Neurochem Int 128:94. https:\/\/doi.org\/10.1016\/J.NEUINT.2019.04.010","journal-title":"Neurochem Int"},{"key":"2109_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/J.MOLMET.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR et al (2019) Glucagon-like peptide 1 (GLP-1). Mol Metab 30:72\u2013130. https:\/\/doi.org\/10.1016\/J.MOLMET.2019.09.010","journal-title":"Mol Metab"},{"key":"2109_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/S41422-022-00692-0","author":"NJ Spencer","year":"2022","unstructured":"Spencer NJ, Hibberd TJ (2022) GLP-1 appetite control via intestinofugal neurons. Cell Res. https:\/\/doi.org\/10.1038\/S41422-022-00692-0","journal-title":"Cell Res"},{"key":"2109_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/J.METABOL.2019.04.014","volume":"96","author":"JJ Holst","year":"2019","unstructured":"Holst JJ (2019) The incretin system in healthy humans: the role of GIP and GLP-1. Metabolism 96:46\u201355. https:\/\/doi.org\/10.1016\/J.METABOL.2019.04.014","journal-title":"Metabolism"},{"key":"2109_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/J.PEPTIDES.2019.170183","author":"LS Gasbjerg","year":"2020","unstructured":"Gasbjerg LS, Bergmann NC, Stensen S et al (2020) Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides. https:\/\/doi.org\/10.1016\/J.PEPTIDES.2019.170183","journal-title":"Peptides"},{"key":"2109_CR13","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.7150\/IJBS.59965","volume":"17","author":"X Ma","year":"2021","unstructured":"Ma X, Liu Z, Ilyas I et al (2021) GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci 17:2050\u20132068. https:\/\/doi.org\/10.7150\/IJBS.59965","journal-title":"Int J Biol Sci"},{"key":"2109_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/J.HJC.2018.11.008","volume":"60","author":"E Andrikou","year":"2019","unstructured":"Andrikou E, Tsioufis C, Andrikou I et al (2019) GLP-1 receptor agonists and cardiovascular outcome trials: an update. Hellenic J Cardiol 60:347\u2013351. https:\/\/doi.org\/10.1016\/J.HJC.2018.11.008","journal-title":"Hellenic J Cardiol"},{"key":"2109_CR15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/CVR\/CVW216","volume":"112","author":"MV Basalay","year":"2016","unstructured":"Basalay MV, Mastitskaya S, Mrochek A et al (2016) Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning. Cardiovasc Res 112:669\u2013676. https:\/\/doi.org\/10.1093\/CVR\/CVW216","journal-title":"Cardiovasc Res"},{"key":"2109_CR16","doi-asserted-by":"publisher","first-page":"8001","DOI":"10.1016\/j.vaccine.2010.09.034","volume":"28","author":"EA Talbot","year":"2010","unstructured":"Talbot EA, Brown KH, Kirkland KB et al (2010) The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine 28:8001\u20138007. https:\/\/doi.org\/10.1016\/j.vaccine.2010.09.034","journal-title":"Vaccine"},{"key":"2109_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/J.TEM.2019.09.003","volume":"31","author":"T Hira","year":"2020","unstructured":"Hira T, Pinyo J, Hara H (2020) What Is GLP-1 really doing in obesity? Trends Endocrinol Metab 31:71\u201380. https:\/\/doi.org\/10.1016\/J.TEM.2019.09.003","journal-title":"Trends Endocrinol Metab"},{"key":"2109_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2020.00178","author":"MP Gilbert","year":"2020","unstructured":"Gilbert MP, Pratley RE (2020) GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/FENDO.2020.00178","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2109_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2021.721135","author":"X Zhao","year":"2021","unstructured":"Zhao X, Wang M, Wen Z et al (2021) GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/FENDO.2021.721135","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Suppl 1","key":"2109_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/DOM.13162","volume":"20","author":"VR Aroda","year":"2018","unstructured":"Aroda VR (2018) A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab 20(Suppl 1):22\u201333. https:\/\/doi.org\/10.1111\/DOM.13162","journal-title":"Diabetes Obes Metab"},{"key":"2109_CR21","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMOA1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly AS, Auerbach P, Barrientos-Perez M et al (2020) A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med 382:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMOA1916038","journal-title":"N Engl J Med"},{"key":"2109_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/J.JPEDS.2021.05.009","volume":"236","author":"PM Ryan","year":"2021","unstructured":"Ryan PM, Seltzer S, Hayward NE et al (2021) Safety and efficacy of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity: a meta-analysis. J Pediatr 236:137-147.e13. https:\/\/doi.org\/10.1016\/J.JPEDS.2021.05.009","journal-title":"J Pediatr"},{"key":"2109_CR23","unstructured":"FDA approves weight management drug for patients aged 12 and older | FDA. In: U.S. FOOD DRUG Adm. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-weight-management-drug-patients-aged-12-and-older. Accessed 18 Oct 2022"},{"key":"2109_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/J.EPRAC.2020.10.013","volume":"27","author":"A Brener","year":"2021","unstructured":"Brener A, Peleg I, Rosenfeld T et al (2021) Beyond body mass index - body composition assessment by bioimpedance in routine endocrine practice. Endocr Pract 27:419\u2013425. https:\/\/doi.org\/10.1016\/J.EPRAC.2020.10.013","journal-title":"Endocr Pract"},{"key":"2109_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/J.2047-6310.2013.00168.X","volume":"9","author":"HD McCarthy","year":"2014","unstructured":"McCarthy HD, Samani-Radia D, Jebb SA, Prentice AM (2014) Skeletal muscle mass reference curves for children and adolescents. Pediatr Obes 9:249\u2013259. https:\/\/doi.org\/10.1111\/J.2047-6310.2013.00168.X","journal-title":"Pediatr Obes"},{"issue":"28","key":"2109_CR26","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"287","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS et al (1985) (1985) Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetol 287(28):412\u2013419. https:\/\/doi.org\/10.1007\/BF00280883","journal-title":"Diabetol"},{"key":"2109_CR27","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-1349","author":"SR Daniels","year":"2008","unstructured":"Daniels SR, Greer FR (2008) Lipid screening and cardiovascular health in childhood. Pediatrics. https:\/\/doi.org\/10.1542\/peds.2008-1349","journal-title":"Pediatrics"},{"key":"2109_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2022.852290","author":"AK Nur ZatiIwani","year":"2022","unstructured":"Nur ZatiIwani AK, Jalaludin MY, Yahya A et al (2022) TG: HDL-C ratio as insulin resistance marker for metabolic syndrome in children with obesity. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/FENDO.2022.852290","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2109_CR29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, Sasso M, Deeks JJ et al (2020) FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 5:362\u2013373. https:\/\/doi.org\/10.1016\/S2468-1253(19)30383-8","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2109_CR30","unstructured":"VCV000435828.8 - ClinVar - NCBI. https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/435828\/?new_evidence=true. Accessed 8 Nov 2022"},{"key":"2109_CR31","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/METABO12050430","volume":"12","author":"R Grinbaum","year":"2022","unstructured":"Grinbaum R, Beglaibter N, Mitrani-Rosenbaum S et al (2022) The Obesogenic and glycemic effect of bariatric surgery in a family with a melanocortin 4 receptor loss-of-function mutation. Metabolites 12:430. https:\/\/doi.org\/10.3390\/METABO12050430","journal-title":"Metabolites"},{"key":"2109_CR32","unstructured":"Maturity-Onset Diabetes of the Young, Type 3 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials. https:\/\/www.malacards.org\/card\/maturity_onset_diabetes_of_the_young_type_3?showAll=True. Accessed 8 Nov 2022"},{"key":"2109_CR33","unstructured":"NM_000527.5(LDLR):c.1720C>T (p.Arg574Cys) AND Hypercholesterolemia, familial, 1 - ClinVar - NCBI. https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/RCV000238063\/. Accessed 8 Nov 2022"},{"key":"2109_CR34","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMOA2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384:1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMOA2028395","journal-title":"N Engl J Med"},{"key":"2109_CR35","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1515\/CCLM.2010.315\/MACHINEREADABLECITATION\/RIS","volume":"48","author":"F Ceriotti","year":"2010","unstructured":"Ceriotti F, Henny J, Queralt\u00f3 J et al (2010) Common reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and \u03b3-glutamyl transferase (GGT) in serum: results from an IFCC multicenter study. Clin Chem Lab Med 48:1593\u20131601. https:\/\/doi.org\/10.1515\/CCLM.2010.315\/MACHINEREADABLECITATION\/RIS","journal-title":"Clin Chem Lab Med"},{"key":"2109_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/AJG.2016.517","volume":"112","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, Cohen SM, Lim JK (2017) ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol 112:18\u201335. https:\/\/doi.org\/10.1038\/AJG.2016.517","journal-title":"Am J Gastroenterol"},{"key":"2109_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/J.XCRM.2020.100006","author":"EW Iepsen","year":"2020","unstructured":"Iepsen EW, Have CT, Veedfald S et al (2020) GLP-1 receptor agonist treatment in morbid obesity and type 2 diabetes due to pathogenic homozygous melanocortin-4 receptor mutation: a case report. Cell reports Med. https:\/\/doi.org\/10.1016\/J.XCRM.2020.100006","journal-title":"Cell reports Med"},{"key":"2109_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.4093\/DMJ.2019.0018","volume":"44","author":"JH Bae","year":"2020","unstructured":"Bae JH, Choi HJ, Cho KIK et al (2020) Glucagon-like peptide-1 receptor agonist differentially affects brain activation in response to visual food cues in lean and obese individuals with type 2 diabetes mellitus. Diabetes Metab J 44:248. https:\/\/doi.org\/10.4093\/DMJ.2019.0018","journal-title":"Diabetes Metab J"},{"key":"2109_CR39","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2337\/DC13-3007","volume":"37","author":"SH \u00d8stoft","year":"2014","unstructured":"\u00d8stoft SH, Bagger JI, Hansen T et al (2014) Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. Diabetes Care 37:1797\u20131805. https:\/\/doi.org\/10.2337\/DC13-3007","journal-title":"Diabetes Care"},{"key":"2109_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/METABO11020073","volume":"11","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G et al (2021) Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites 11:1\u201313. https:\/\/doi.org\/10.3390\/METABO11020073","journal-title":"Metabolites"},{"key":"2109_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBAMCR.2022.119300","author":"L Wu","year":"2022","unstructured":"Wu L, Zhou M, Li T et al (2022) GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R\/AMPK pathway. Biochim Biophys acta Mol cell Res. https:\/\/doi.org\/10.1016\/J.BBAMCR.2022.119300","journal-title":"Biochim Biophys acta Mol cell Res"},{"key":"2109_CR42","doi-asserted-by":"publisher","first-page":"111472","DOI":"10.1016\/J.MCE.2021.111472","volume":"539","author":"S Yamada","year":"2022","unstructured":"Yamada S, Ogura Y, Inoue K et al (2022) Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats. Mol Cell Endocrinol 539:111472. https:\/\/doi.org\/10.1016\/J.MCE.2021.111472","journal-title":"Mol Cell Endocrinol"},{"key":"2109_CR43","doi-asserted-by":"publisher","first-page":"e13202","DOI":"10.1111\/ACEL.13202","volume":"19","author":"H Abdulla","year":"2020","unstructured":"Abdulla H, Phillips BE, Wilkinson DJ et al (2020) Glucagon-like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle. Aging Cell 19:e13202. https:\/\/doi.org\/10.1111\/ACEL.13202","journal-title":"Aging Cell"},{"key":"2109_CR44","doi-asserted-by":"publisher","first-page":"154044","DOI":"10.1016\/J.METABOL.2019.154044","volume":"103","author":"AA Gurjar","year":"2020","unstructured":"Gurjar AA, Kushwaha S, Chattopadhyay S et al (2020) Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents. Metabolism 103:154044. https:\/\/doi.org\/10.1016\/J.METABOL.2019.154044","journal-title":"Metabolism"},{"key":"2109_CR45","doi-asserted-by":"publisher","DOI":"10.2174\/1573399819666220610150342","author":"E Ayan","year":"2022","unstructured":"Ayan E, DeMirci H (2022) A brief atlas of insulin. Curr Diabetes Rev. https:\/\/doi.org\/10.2174\/1573399819666220610150342","journal-title":"Curr Diabetes Rev"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-023-02109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-023-02109-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-023-02109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T18:49:40Z","timestamp":1687546180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-023-02109-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["2109"],"URL":"https:\/\/doi.org\/10.1007\/s00592-023-02109-9","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"assertion":[{"value":"28 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The institutional ethics committee after careful consideration and deliberation in each case approved the off-label use of liraglutide.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The patients and their parents gave their informed consent to publish their case.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}